Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

All GLG News Analyses Filed Under: Infectious Disease

Articles with lock require a GLG News subscription
Posted January 14, 2008
Great if it works
Analysis of: Universal flu vaccine shows early promise | www.fiercebioresearcher.com
Author: GLG Member Program Contributor
A vaccine that combats all forms of flu-WOW. Let us see further results first.
Posted January 14, 2008
New Pharmasset/Roche HCV polymerase inhibitor R7128 is promising in combination therapy
Analysis of: Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C | www.hivandhepatitis.com
Author: GLG Member Program Contributor
In this small pilot study, R7128 at 1500 mg twice daily combined with Pegasys + ribavirin led to a rapid viral response (HVC RNA <15 IU/mL at week 4) in 85% of patients compared with  35% at 500 mg twice daily and 10% with Pegasys + ribavirin alone.  R7128 did not add much toxicity...
Posted January 9, 2008
What is the value of HPV vaccines?
Analysis of:  Ouch! Cervical cancer shots painful | news.yahoo.com
Author: GLG Member Program Contributor
If you read the CDC analysis of January 2007, you would conclude that both the Merck and GSK vaccines offer little advantage to females under 30 years of age. Why the enormous campaign then by the marketers of these vaccines to get them in use? Since they only cover 70% of the high risk strains anyway,...
Posted January 9, 2008
We need better antibiotics
Analysis of: Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741 | www.pipelinereview.com
Author: GLG Member Program Contributor
This drug which clearly focuses on antibiotic resistant strains  will be a welcome addition if it does not have significant side effects.
Posted January 8, 2008
Yeah, injections hurt....
Analysis of:  Ouch! Cervical cancer shots painful | news.yahoo.com
Author: GLG Member Program Contributor
Ever had a sore arm for two days following a tetanus vaccine?
Posted January 8, 2008
New Broad Spectrum Antibiotic - 2 New Phase 2 Studies
Analysis of: Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741 | www.pipelinereview.com
Author: GLG Member Program Contributor
Successful completion of these studies in community acquired pneumonia and skin and soft tissue infection will hopefully lead to approval of an additional new drug active against drug resistant bacteria, such as MRSA.
Posted January 8, 2008
ouch! should not cut it.
Analysis of:  Ouch! Cervical cancer shots painful | news.yahoo.com
Author: GLG Member Program Contributor
The benefit/risk  ratio is so positive that this should be NO excuse not to use the vaccine.
Posted January 3, 2008
Benchmarking Gone Amok
Analysis of: Ventilator-associated pneumonia - the wrong quality measure for benchmarking | www.annals.org
Author: GLG Member Program Contributor
Hospitals and physicians are under increasing pressure to follow benchmarks or be penalized. When this happens and when already lean payments are cut further, how can that lead to an increase in quality?
Posted January 3, 2008
VAP reporting - the wrong quality measure to report
Analysis of: Ventilator-associated pneumonia - the wrong quality measure for benchmarking | www.annals.org
Author: GLG Member Program Contributor
Ventilator-associated pneumonia (VAP) is a disease with high mortality. However, it is notoriously difficult to diagnose. Although rates of VAP may appear to be an important quality measure, the diagnostic difficulties make this a poor measure upon which hospitals should be compared.
Posted January 2, 2008
New Treatment for Chronic Hepatitis C Infection
Analysis of: GlobeImmune Announces Initiation of Phase II Clinical Trial of GI-5005 in Patients with Chronic Hepatitis C | www.pipelinereview.com
Author: GLG Member Program Contributor
This approach is different in that it makes use of the immune response to help clear the virus. As with all new drugs for this indication, it is being studied as an addition to standard therapy which is effective in gentoype 1 infection only about 50% of the time. 
Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next51 to 60 of 218

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-10-07T13:45:18.680